Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Novavax (NVAX) stock has outperformed the S&P 500 over the past month, and while the current quarter is projected to show a loss, annual earnings estimates for the current fiscal year have been revised upward significantly. Revenue estimates show near-term decline but overall growth for the current fiscal year. Despite positive earnings and revenue surprises in the last reported quarter, Novavax holds a Zacks Rank #3 (Hold), suggesting near-term performance in line with the broader market; however, its Value Style Score of B indicates it may be undervalued compared to its peers.

Analysis

Novavax (NVAX) has exhibited notable recent stock performance, returning +8.7% over the past month, outpacing both the Zacks S&P 500 composite's +8.2% and its Zacks Medical - Biomedical and Genetics industry's +0.2% gain. Despite this, near-term earnings projections are challenging, with an expected loss of $0.08 per share for the current quarter, a significant -108.1% year-over-year decline, and a Zacks Consensus Estimate revision of -137.7% over the last 30 days for this period. However, the outlook for the current fiscal year is considerably more positive, with a consensus earnings estimate of $1.46, representing a +218.7% year-over-year increase; this estimate has seen a substantial upward revision of +132.8% in the past 30 days. Conversely, the next fiscal year's consensus earnings estimate of $0.42 indicates a potential -71.7% contraction from the current year's expected earnings, though this estimate has risen +1.6% in the last month. Revenue forecasts mirror this mixed outlook: a projected -68.1% year-over-year decline for the current quarter to $132.57 million, but an anticipated +19.8% increase to $817.53 million for the current fiscal year, followed by a -37.3% decrease to $512.93 million for the next fiscal year. Novavax's last reported quarter showed exceptionally strong results, with revenues of $666.66 million (+610.3% YoY) and EPS of $2.93 (versus -$1.05 YoY), surpassing consensus estimates by +215.04% and +312.68% respectively. The company has a track record of beating consensus EPS and revenue estimates three times in the last four quarters. Despite these strong historical surprises and positive full-year revisions, Novavax currently holds a Zacks Rank #3 (Hold), suggesting its near-term performance may align with the broader market. Its Zacks Value Style Score of B, however, indicates it may be trading at a discount relative to its peers.

Key Decisions for Investors

• Investors should acknowledge the conflicting signals: strong recent stock momentum and significant upward revisions for current fiscal year earnings against a projected near-term quarterly loss and a substantial earnings decline forecasted for the next fiscal year.
• Consider the Zacks Rank #3 (Hold) which suggests near-term market-perform expectations, while the Value Style Score of B implies potential undervaluation that warrants further due diligence.
• Closely monitor upcoming earnings reports and revenue trends, given the high volatility in estimate revisions and the company's history of significant earnings surprises, to assess the sustainability of its revenue and profit generation beyond the current fiscal year's upswing.
• Evaluate risk tolerance in light of the sharp projected decline in revenue and earnings for the next fiscal year, which could impact long-term valuation despite current year strength.